CN107773687A - A kind of pharmaceutical composition for being used to treat burn and scald - Google Patents
A kind of pharmaceutical composition for being used to treat burn and scald Download PDFInfo
- Publication number
- CN107773687A CN107773687A CN201610754003.3A CN201610754003A CN107773687A CN 107773687 A CN107773687 A CN 107773687A CN 201610754003 A CN201610754003 A CN 201610754003A CN 107773687 A CN107773687 A CN 107773687A
- Authority
- CN
- China
- Prior art keywords
- extract
- pharmaceutical composition
- parts
- scald
- burn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 50
- 229920001661 Chitosan Polymers 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 240000002734 Lonicera caerulea Species 0.000 claims abstract description 10
- 235000001387 Lonicera caerulea Nutrition 0.000 claims abstract description 10
- 241001646834 Mesona Species 0.000 claims abstract description 10
- 241000746966 Zizania Species 0.000 claims abstract description 10
- 235000002636 Zizania aquatica Nutrition 0.000 claims abstract description 10
- 241000245301 Nymphoides Species 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 229940105022 spearmint extract Drugs 0.000 claims abstract description 9
- 241001671201 Tetracera Species 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 230000009849 deactivation Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 2
- 150000001243 acetic acids Chemical class 0.000 claims description 2
- 229940106157 cellulase Drugs 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 7
- 241000588724 Escherichia coli Species 0.000 abstract description 5
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 231100000252 nontoxic Toxicity 0.000 abstract description 4
- 230000003000 nontoxic effect Effects 0.000 abstract description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000029663 wound healing Effects 0.000 abstract description 3
- 230000037314 wound repair Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000006101 laboratory sample Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for being used to treat burn and scald, the new pharmaceutical composition is made up of the composition of following weight：8 parts of chitosan oligomer 2 part, 2 parts of Chinese mesona herb extract 1 part, 0.5 part of 1.5 0.5 part 1.5 parts of Fen , Nymphoides Lays extract of Lonicera caerulea extract, 1 part of wild rice root extract 0.5 part, 1 part of spearmint extract 0.5 part, 1 part of asian tetracera root or leaf extract 0.5 part.The present inventor has carried out acute toxicity testing to described pharmaceutical composition, as a result shows that the pharmaceutical composition of the present invention can be considered nontoxic.Antibacterial experiment in vitro shows that the drug regimen has good inhibition to staphylococcus aureus, Escherichia coli, pseudomonas aeruginosa.Wound repair experiment shows that the pharmaceutical composition has good effect to wound healing.Cell proliferation experiment shows that the pharmaceutical composition has good cell repair and regeneration function.Therefore, pharmaceutical composition of the invention can be used for treating burn and scald, there is larger clinical value and social benefit.Preparation method of the present invention is simple, is suitable for industrialized production.
Description
Technical field
The present invention relates to pharmaceutical composition, and in particular to a kind of pharmaceutical composition for being used to treat burn and scald.
Background technology
Burn and scald, is unexpected injury common in life, and boiling water, rolling congee, deep fat, the burning of heat steam are scalded and often occurred.It is right
Some burn and scalds, if processing is not in time, it may result in wound infection, even high fever, the adverse consequences such as general infection.
At present, based on the research to chitosan, having reported it has antibacterial, antitumor, Adjust-blood lipid, regulation immune and promotees
Enter the multiple functions such as wound reparation, but because of its poorly water-soluble, greatly limit the application in biomedicine field.The present inventor is led to
Enzyme edman degradation Edman is crossed, by degradation of chitosan into the degree of polymerization is small, water-soluble big chitosan oligomer.And it has been investigated that oligomeric shell
Glycan has free amine group, can be combined with negatively charged cell membrane rapidly, strengthens bacterial cell membrane permeability, cell content
Beyond the region of objective existence stream, so as to bacteria growing inhibiting；Chitosan can accelerate the secretion of collagen, so as to promote granulation tissue and epithelium group
The formation knitted, promote the quick healing of burn and scald mouth.
However, the present inventor further study show that, such as individually by chitosan oligomer be used for treat burn and scald when, effect is simultaneously
Not significantly, when adding other compositions pharmaceutical composition is made, it has the effect of more preferable to wound healing, is controlled available for burn and scald
Treat.Thus, preferably actively study oligopolymerization chitosan sugar composite and its new indication.
The content of the invention
The technical problems to be solved by the invention are to overcome above-mentioned weak point, medicine of the research and design containing chitosan oligomer
Compositions and its clinical practice.
The invention provides a kind of pharmaceutical composition for being used to treat burn and scald.
The pharmaceutical composition of the present invention is made up of the composition of following weight：2 parts -8 parts of chitosan oligomer, Chinese mesona herb
1 part -2 parts of extract, 0.5 part of -1.5 0.5 part -1.5 parts of Fen , Nymphoides Lays extract of Lonicera caerulea extract, 0.5 part -1 of wild rice root extract
Part, 0.5 part -1 part of spearmint extract, 0.5 part -1 part of asian tetracera root or leaf extract.
Preferably, pharmaceutical composition of the invention is made up of the composition of following weight proportion：5 parts of chitosan oligomer, bean jelly
Careless 1.5 parts of extract, 1 part of the Fen , Nymphoides Lays extract of Lonicera caerulea extract 1,0.8 part of wild rice root extract, spearmint extract 0.8
Part, 0.75 part of asian tetracera root or leaf extract.
It is a further object of the present invention to provide the preparation method of described pharmaceutical composition, this method is：
Chitosan oligomer, Chinese mesona herb extract, Lonicera caerulea extract, Nymphoides Lays extract, wild rice root extract, spearmint extract,
Asian tetracera root or leaf extract is mixed together with water, and being sufficiently stirred makes it uniformly boil 5min, is cooled to 25 DEG C ± 2 DEG C of room temperature, crosses and filters out
Insoluble matter is removed, is produced.
In pharmaceutical composition of the present invention, the mean molecule quantity of the chitosan oligomer is 1000-2400, by following
It is prepared by method：
By the chitosan 10g acetic acids that 330ml concentration is 1%, chitosan concentration 0.03g/ml, cellulase is added
5ml（45u containing enzyme amount）Hydrolysis, hydrolyze 20mim after adjust pH value to 6.0,50 DEG C continue degrade 6h, 100 DEG C of enzyme deactivation 15min, from
The heart takes supernatant, freeze-drying, obtains chitosan oligomer 9.13g.Tested through HPLC, confirm as chitosan oligomer, mean molecule
Measure as 1800.
The Chinese mesona herb extract, Lonicera caerulea extract, folium eucalypti extract, wild rice root extract, spearmint extract, Xi Ye
The raw materials such as boisiana extract are by being commercially available.
It is yet another object of the invention to provide described pharmaceutical composition to prepare the application in treating burn and scald medicine.
The present inventor has carried out acute toxicity testing to described pharmaceutical composition, as a result shows the pharmaceutical composition of the present invention
It can be considered nontoxic.Antibacterial experiment in vitro shows the drug regimen to staphylococcus aureus, Escherichia coli, pseudomonas aeruginosa
There is good inhibition.Wound repair experiment shows that the pharmaceutical composition has good effect to wound healing.Cell increases
Grow experiment and show that the pharmaceutical composition has good cell repair and regeneration function.
The pharmaceutical composition of the present invention solves the problems, such as that other clinical medicine toxicity are big or wound repairing effect is bad,
Pharmaceutical composition of the present invention is non-toxic, significant effect, has larger clinical value and social benefit for treating burn and scald.
Preparation method of the present invention is simple, is suitable for industrialized production.
Embodiment
The preparation of the chitosan oligomer of embodiment 1（Enzyme process）.
By chitosan 10g（Degree of deacetylation 95%, moisture 4.85%, ash content 0.5%, mean molecule quantity 100,000, purchased from Jinan
Hai get Bei ocean engineerings Co., Ltd）Dissolved, chitosan concentration 0.03g/ml, added fine with the acetic acid 330ml that concentration is 1%
Tie up plain enzyme 5ml（45u containing enzyme amount）Hydrolysis, hydrolyze 20mim after adjust pH value to 6.0,50 DEG C continue degrade 4h, 100 DEG C of enzyme deactivations
15min, centrifuging and taking supernatant, freeze-drying, obtain chitosan oligomer 9.13g.Tested through HPLC, confirm as chitosan oligomer,
Mean molecule quantity is 1800.
The preparation of the pharmaceutical composition of embodiment 2.
Chitosan oligomer purity >=98.5%, mean molecule quantity 1800, embodiment 1 are made.
Following composition raw material is commercially available：
Chinese mesona herb extract Chinese mesona herb polyoses content >=30%；
Lonicera caerulea extract volatile oil total content >=15%；
Nymphoides Lay extract rutin sophorin content >=10%；
Wild rice root extract total reducing sugars Content >=10%；
Spearmint extract volatile oil total content >=8%；
Asian tetracera root or leaf extract lupeol content >=5%.
200ml beakers are taken, 100ml is added and removes thermal source distilled water, then add 5g chitosan oligomers, the extraction of 1.5g Chinese mesona herbs
Thing, 1.0g Lonicera caerulea extracts, 1.0g Nymphoides Lay extracts, 0.8g wild rice root extracts, 0.8g spearmint extracts, 0.75g tin leaves
Boisiana extract, being sufficiently stirred makes it well mixed, boils 5min, is cooled to 25 DEG C of room temperature, is filtered to remove insoluble matter, produces medicine
Composition 103.5g.
Pharmaceutical composition made from embodiment 2 is used for following experiments.
The acute toxicity testing of embodiment 3.
Experimental animal：Kunming mice 70,17 ~ 22g of body weight, male and female half and half are limited purchased from Shanghai Si Laike experimental animals
Company.
Animal packet：Distinguish the Stochastic Equilibrium method of dividision into groups using male and female, be divided into 7 groups, every group 10, one of which is blank
Control group.
Laboratory sample：It is made in embodiment 2.
Dosage determines：Dose design is 3ml/kg, 10ml/kg, 50ml/kg, 100ml/kg.
Administration：Disposable gastric infusion：3 ~ 5h of fasting before administration, after administration 1 ~ 2h of fasting, fasting can't help water.Using in batches
Administration, control group, 3ml/kg groups, 10ml/kg groups first administrations, determined after administration set by dosage it is suitable, then give 50ml/kg
Group and 100ml/kg groups.Continuous Observation more than 7 days after administration, then morning and afternoon is respectively observed once daily, Continuous Observation 14 days.In detail
Every observation index is carefully recorded, the results are shown in Table 1.
Table 1.
Conclusion：Tested material is when gastric infusion dosage reaches 100ml/kg in this experiment（Solid equivalent to 7.2mg/kg
Medicine）, do not occur death.Judge according to acute toxicity grading criteria, this test medicine can be considered nontoxic.
The antibacterial experiment in vitro of embodiment 4.
Bacterial strain：Staphylococcus aureus, Escherichia coli, pseudomonas aeruginosa.
Buffer solution：PH7.0 sterile NaCl peptone buffer agents.
Culture medium：Plain agar culture medium.
Laboratory sample：Embodiment 2 is made.
Experimental temperature：20℃±1℃.
Experimental method：At 20 DEG C ± 1 DEG C, it is false that laboratory sample is acted on into staphylococcus aureus, Escherichia coli, verdigris
Monad, action time 2min, 5min, 10min, 20min, observation experiment result.Experiment is repeated 3 times.Experimental result is shown in Table
2。
Table 2.
Conclusion：At 20 DEG C ± 1 DEG C, tested material has to staphylococcus aureus, Escherichia coli, pseudomonas aeruginosa
Extremely strong bacteriostasis.
The mucocutaneous impaired wound repair experiment of embodiment 5.
Experimental animal：C57 mouse, 16-18g, male, purchased from Shanghai Slac Experimental Animal Co., Ltd..It is real
Proved recipe method：By experiment mice blank group, control group 1（U.S.'s 3M medical adhesive tapes）, control group 2（Britain applies expensive precious Convatee productions
Product）, control group 3（Golden English peptide EGF）, experimental group.Every group 20.Mouse back unhairing otch modeling, surface of a wound iodophor disinfection, so
Afterwards with appropriate physiological saline debridement, then the product of control group 1, the product of control group 2 are covered in the surface of a wound respectively；Spray control group 3
Product and experimental group medicine, spontaneously dry, are then covered with sterile gauze.Feelings were replied with regard to the wound of 3 days, 7 days and 14 days respectively
Condition is compareed.Experimental result is shown in Table 3.
Table 3.
Conclusion：Experimental group curative effect is significantly better than other groups, can repair the impaired surface of a wound.
The cell proliferation experiment of embodiment 6
Cell line：People's epidermis protein cell line colo-16.
Reagent：Culture medium：DMEM, containing 10% hyclone, 100ug/ml penicillin, 100ug/ml streptomysin.
MTT, the solution of 5mg/ml concentration is made into using the preceding PBS with PH7.2.
DMSO is inoculated with epidermal cell, when the colo-16 cell growths of culture are close to individual layer, draws supernatant in bottle, uses
0.3% Trypsin Induced, adds appropriate DMEM that cell monolayer suspension, inoculation and 96 orifice plates are made, and 37 DEG C 5% is put per hole 200uL
CO2gas incubator culture.
Drug-treated：After inoculation 24 hours, each hole supernatant and non-attached cell are drawn, is separately added into control group 1（Peace
Skin relaxes）, control group 2（Golden English peptide EGF）, experimental group.After dosing, continue culture 72 hours, cell is observed under inverted microscope
Proliferative conditions.Experimental result is shown in Table 4.
Table 4.
Conclusion：Pharmaceutical composition is good to the propagation and regeneration function of cell.
Claims (8)
1. a kind of pharmaceutical composition for being used to treat burn and scald, it is characterised in that described pharmaceutical composition is matched somebody with somebody by following parts by weight
The composition composition of ratio：2 parts -8 parts of chitosan oligomer, 1 part -2 parts of Chinese mesona herb extract, 0.5 part of -1.5 Fen , Nymphoides of Lonicera caerulea extract
0.5 part -1.5 parts of Lay extract, 0.5 part -1 part of wild rice root extract, 0.5 part -1 part of spearmint extract, asian tetracera root or leaf extract 0.5
- 1 part of part.
2. a kind of pharmaceutical composition for being used to treat burn and scald, it is characterised in that described pharmaceutical composition is matched somebody with somebody by following parts by weight
The composition composition of ratio：5 parts of chitosan oligomer, 1.5 parts of Chinese mesona herb extract, 1 part of the Fen , Nymphoides Lays extract of Lonicera caerulea extract 1, wild rice
0.8 part of root extract, 0.8 part of spearmint extract, 0.75 part of asian tetracera root or leaf extract.
3. a kind of preparation method for being used to treat the pharmaceutical composition of burn and scald as claimed in claim 1 or 2, its feature exist
In this method is：Chitosan oligomer, Chinese mesona herb extract, Lonicera caerulea extract, Nymphoides Lays extract, wild rice root extract, spearmint
Extract, asian tetracera root or leaf extract and water are mixed together, and being sufficiently stirred makes it uniformly boil 5min, be cooled to room temperature 25 DEG C ± 2
DEG C, insoluble matter is filtered to remove, is produced.
4. preparation method according to claim 3, it is characterised in that the dosage of the water is 5-20 times of raw material gross weight
Amount, preferably 12 times amounts.
5. preparation method according to claim 3, it is characterised in that the chitosan oligomer is prepared by the following method：
By the chitosan 10g acetic acids that 330ml concentration is 1%, chitosan concentration 0.03g/ml, cellulase is added
5ml （45u containing enzyme amount）Hydrolysis, hydrolyze 20mim after adjust pH value to 6.0,50 DEG C continue degrade 6h, 100 DEG C of enzyme deactivation 15min, from
The heart takes supernatant, freeze-drying, obtains chitosan oligomer 9.13g.
6. the preparation method according to claim 3 or 5, it is characterised in that the mean molecule quantity of the chitosan oligomer is
1000-2400。
7. a kind of pharmaceutical composition as claimed in claim 1 is preparing the application in treating burn and scald medicine.
A kind of 8. pharmaceutical composition for being used to treat burn and scald answering in burn and scald medicine is prepared as claimed in claim 2
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610754003.3A CN107773687A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition for being used to treat burn and scald |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610754003.3A CN107773687A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition for being used to treat burn and scald |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107773687A true CN107773687A (en) | 2018-03-09 |
Family
ID=61441298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610754003.3A Pending CN107773687A (en) | 2016-08-30 | 2016-08-30 | A kind of pharmaceutical composition for being used to treat burn and scald |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107773687A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727581A (en) * | 2011-04-11 | 2012-10-17 | 苏州瑞美科生物技术有限公司 | Pharmaceutical composition with wound repairing effect |
-
2016
- 2016-08-30 CN CN201610754003.3A patent/CN107773687A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727581A (en) * | 2011-04-11 | 2012-10-17 | 苏州瑞美科生物技术有限公司 | Pharmaceutical composition with wound repairing effect |
Non-Patent Citations (2)
| Title |
|---|
| 柴平海等: "低聚壳聚糖功能性质及应用 ", 《大学化学》 * |
| 段杉等: "低聚壳聚糖的制备及应用 ", 《中国食品添加剂》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ge et al. | Taraxacum mongolicum protects against Staphylococcus aureus-infected mastitis by exerting anti-inflammatory role via TLR2-NF-κB/MAPKs pathways in mice | |
| CN113244296B (en) | Medicinal volatile oil composition and preparation method and application thereof | |
| US6455070B1 (en) | Composition for treating symptoms of influenza | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| KR20110100329A (en) | Herbal medicine composition for the inhibition of angiogenesis | |
| CN106265822A (en) | There are anti-inflammation raw myofunctional Mahonia bealei (Fort.) Carr. extract, preparation method and applications | |
| CN100502894C (en) | Method for preparing medicine of effective parts extracted from myrobalan for treating diseases infected by bacteria or virus | |
| CN102727581B (en) | A kind of pharmaceutical composition wound to repair | |
| Mbakwem-Aniebo et al. | Effects of Ficus exasperata Vahl on common dermatophytes and causative agent of Pityriasis Versicolor in rivers state, Nigeria | |
| CN102727579A (en) | Pharmaceutical composition for treatment of oral ulcers | |
| CN107773687A (en) | A kind of pharmaceutical composition for being used to treat burn and scald | |
| JP4398172B2 (en) | Infection prevention and treatment agent for fish | |
| CN111905058A (en) | Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof | |
| CN112516183B (en) | Preparation method and application of extract with repair effect on trauma | |
| CN107789393A (en) | A kind of pharmaceutical composition for treating wound caused by chemicotherapy | |
| CN107789480A (en) | A kind of pharmaceutical composition for being used to treat canker sore | |
| Xu et al. | Application of Atractylodes Macrocephala Koidz Extract in Methicillin-Resistant Staphylococcus Aureus | |
| CN102727577A (en) | Medicinal composition for treating gynecological inflammations | |
| CN109999086A (en) | Treat pig polyserositis and arthritic Chinese medicine composition and preparation method thereof | |
| CN112168929A (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN107773724A (en) | A kind of pharmaceutical composition for being used to treat gynaecological imflammation | |
| CN110025643B (en) | Compound with anticancer activity and preparation method and application thereof | |
| Naghsh et al. | Investigation between alcoholic extract and essential oil melissa officinalis L. new in growth inhibition of E. coli | |
| WO2013147409A1 (en) | Natural extract for preventing and treating oral disease | |
| CN104257913A (en) | Traditional Chinese medicine concentrated solution for treating cow mastitis and coating agent prepared from concentrated solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180309 |